FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology and is a system for the induced expression of a polynucleotide encoding a chimeric antigen receptor (CAR). This system includes an induced promoter, a constitutive promoter, an activating stimulator, including anti-CD3 and/or anti-CD28 antibodies, and tamoxifen, a tamoxifen metabolite, or a tamoxifen analog. The present invention also discloses a host cell containing the specified system for cellular immunotherapy, a method to obtain that, a pharmaceutical composition containing the specified cell, as well as a method for implementing immunotherapy using the specified cell.
EFFECT: present invention makes it possible to obtain genetic constructs containing CAR for the treatment of cancer, which provide increased survival and effectiveness under in vivo conditions, while minimizing undesirable side effects.
31 cl, 14 tbl, 19 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| TRANSGENIC GENETIC LABELS AND METHODS OF USING | 2015 |
|
RU2729112C2 |
| METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY | 2015 |
|
RU2752275C2 |
| PRODUCTS OF A CERTAIN COMPOSITION CONTAINING GENETICALLY MODIFIED T CELLS | 2015 |
|
RU2751921C2 |
| CHIMERIC RECEPTORS CONTAINING TRAF-6-INDUCING DOMAINS AND COMPOSITIONS AND METHODS RELATED TO THEM | 2016 |
|
RU2773159C2 |
| RITUXIMAB-RESISTANT CHIMERIC ANTIGEN RECEPTORS AND WAYS OF USE THEREOF | 2020 |
|
RU2816370C2 |
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| OPTIONS, COMPOSITIONS, AND METHODS FOR USE OF ENDONUCLEASE CBLB | 2018 |
|
RU2779097C2 |
| MODIFIED HEMATOPOIETIC STEM CELLS/PROGENITOR CELLS AND NON-T EFFECTOR CELLS, AND USE THEREOF | 2014 |
|
RU2733652C2 |
| T-CELL COMPOSITIONS WITH T-CELL RECEPTOR DEFICIENCY | 2013 |
|
RU2781979C2 |
| METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
